Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer (original) (raw)

• Petrelli, A. & Giordano, S. From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr. Med. Chem. 15, 422–432 (2008).
  Article CAS PubMed Google Scholar
• Podar, K. et al. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc. Natl Acad. Sci. USA 103, 19478–19483 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Demetri, G. D. et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368, 1329–1338 (2006).
  Article CAS PubMed Google Scholar
• Le Tourneau, C., Faivre, S. & Raymond, E. New developments in multitargeted therapy for patients with solid tumours. Cancer Treat. Rev. 34, 37–48 (2008).
  Article CAS PubMed Google Scholar
• Kerr, D. Clinical development of gene therapy for colorectal cancer. Nature Rev. Cancer 3, 615–622 (2003).
  Article CAS Google Scholar
• Zeimet, A. G. & Marth, C. Why did p53 gene therapy fail in ovarian cancer? Lancet Oncol 4, 415–422 (2003).
  Article CAS PubMed Google Scholar
• McCormick, F. Cancer gene therapy: fringe or cutting edge? Nature Rev. Cancer 1, 130–141 (2001).
  Article CAS Google Scholar
• Rosenberg, S. A., Yang, J. C. & Restifo, N. P. Cancer immunotherapy: moving beyond current vaccines. Nature Med. 10, 909–915 (2004).
  Article CAS PubMed Google Scholar
• Amato, R. J. et al. Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax): a phase 2 trial. J. Immunother. 31, 577–585 (2008).
  Article CAS PubMed Google Scholar
• Gulley, J. L. et al. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin. Cancer Res. 14, 3060–3069 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Heise, C. et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nature Med. 3, 639–645 (1997).
  Article CAS PubMed Google Scholar
• Bell, J. C., Lichty, B. & Stojdl, D. Getting oncolytic virus therapies off the ground. Cancer Cell 4, 7–11 (2003).
  Article CAS PubMed Google Scholar
• Parato, K. A., Senger, D., Forsyth, P. A. & Bell, J. C. Recent progress in the battle between oncolytic viruses and tumours. Nature Rev. Cancer 5, 965–976 (2005).
  Article CAS Google Scholar
• Thorne, S. H., Hermiston, T. & Kirn, D. Oncolytic virotherapy: approaches to tumor targeting and enhancing antitumor effects. Semin. Oncol. 32, 537–548 (2005).
  Article CAS PubMed Google Scholar
• Coffey, M. C., Strong, J. E., Forsyth, P. A. & Lee, P. W. Reovirus therapy of tumors with activated Ras pathway. Science 282, 1332–1334 (1998).
  Article CAS PubMed Google Scholar
• Norman, K. L. & Lee, P. W. Reovirus as a novel oncolytic agent. J. Clin. Invest. 105, 1035–1038 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Stojdl, D. F. et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nature Med. 6, 821–825 (2000).
  Article CAS PubMed Google Scholar
• Stojdl, D. F. et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4, 263–275 (2003).
  Article CAS PubMed Google Scholar
• Bischoff, J. R. et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274, 373–376 (1996).
  Article CAS PubMed Google Scholar
• Heise, C. et al. An adenovirus E1A mutant that demonstrates potent and selective antitumoral efficacy. Nature Med. 6, 1134–1139 (2000).
  Article CAS PubMed Google Scholar
• Mineta, T., Rabkin, S. D., Yazaki, T., Hunter, W. D. & Martuza, R. L. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nature Med. 1, 938–943 (1995).
  Article CAS PubMed Google Scholar
• Mineta, T., Rabkin, S. D. & Martuza, R. L. Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res. 54, 3963–3966 (1994).
  CAS PubMed Google Scholar
• Comins, C. et al. Reovirus: Viral therapy for cancer 'as nature intended'. Clin. Oncol. 20, 548–554 (2008).
  Article CAS Google Scholar
• Kirn, D., Hermiston, T. & McCormick, F. ONYX-015: Clinical data are encouraging. Nature Med. 4, 1341–1342 (1998).
  Article CAS PubMed Google Scholar
• Khuri, F. et al. A controlled trial of Onyx-015, an E1B gene-deleted adenovirus, in combination with chemotherapy in patients with recurrent head and neck cancer. Nature Med. 6, 879–885 (2000).
  Article CAS PubMed Google Scholar
• Nemunaitis, J. et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J. Clin. Oncol. 19, 289–298 (2001).
  Article CAS PubMed Google Scholar
• Reid, T. et al. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Ther. 8, 1618–1626 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Reid, T. et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res. 62, 6070–6079 (2002).
  CAS PubMed Google Scholar
• Liu, T. C., Hwang, T. H., Bell, J. C. & Kirn, D. H. Translation of targeted oncolytic virotherapeutics from the lab into the clinic, and back again: a high-value iterative loop. Mol. Ther. 16, 1006–1008 (2008).
  Article CAS PubMed Google Scholar
• Kim, J. H. et al. Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol. Ther. 14, 361–370 (2006).
  Article CAS PubMed Google Scholar
• Kirn, D. H., Wang, Y., Le Boeuf, F., Bell, J. & Thorne, S. H. Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus. PLoS Med. 4, e353 (2007).
  Article PubMed PubMed Central CAS Google Scholar
• Thorne, S. H. et al. Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. J. Clin. Invest. 117, 3350–3358 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• McCart, J. A. et al. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res. 61, 8751–8757 (2001).
  CAS PubMed Google Scholar
• Guo, Z. S. et al. The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. Cancer Res. 65, 9991–9998 (2005).
  Article CAS PubMed Google Scholar
• Liu, T. C., Hwang, T., Park, B. H., Bell, J. & Kirn, D. H. The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma. Mol. Ther. 16, 1637–1642 (2008).
  Article CAS PubMed Google Scholar
• Park, B. H. et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol. 9, 533–542 (2008).
  Article CAS PubMed Google Scholar
• Moss, B. in Field's Virology Ch. 84 (eds Fields, B. N., Knipe, D.M. & Howley, P. M.) (Lippincott-Raven, Philadelphia, 2001).
  Google Scholar
• Buller, R. M. & Palumbo, G. J. Poxvirus pathogenesis. Microbiol. Rev. 55, 80–122 (1991).
  Article CAS PubMed PubMed Central Google Scholar
• Fenner, F., Henderson, D. A., Arita, I., Jezek, Z. & Ladnyi, I. D. Smallpox and its eradication (World Health Organization, Geneva, 1988).
  Google Scholar
• Enserink, M. Bioterrorism. In search of a kinder, gentler vaccine. Science 296, 1594 (2002).
  Article CAS PubMed Google Scholar
• Cono, J., Casey, C. G. & Bell, D. M. Smallpox vaccination and adverse reactions. Guidance for clinicians. MMWR Recomm. Rep. 52, 1–28 (2003).
  PubMed Google Scholar
• Miller, J. D. et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 28, 710–722 (2008).
  Article CAS PubMed Google Scholar
• Putz, M. M., Midgley, C. M., Law, M. & Smith, G. L. Quantification of antibody responses against multiple antigens of the two infectious forms of Vaccinia virus provides a benchmark for smallpox vaccination. Nature Med. 12, 1310–1315 (2006).
  Article PubMed CAS Google Scholar
• Graham, B. S. et al. Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network. J. Infect. Dis. 170, 782–786 (1994).
  Article CAS PubMed Google Scholar
• Kanesa-thasan, N. et al. Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus — poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans. Vaccine 19, 483–491 (2000).
  Article CAS PubMed Google Scholar
• McClain, D. J., Summers, P. L., Harrison, S. A., Schmaljohn, A. L. & Schmaljohn, C. S. Clinical evaluation of a vaccinia-vectored Hantaan virus vaccine. J. Med. Virol. 60, 77–85 (2000).
  Article CAS PubMed Google Scholar
• Cadoz, M. et al. Immunisation with canarypox virus expressing rabies glycoprotein. Lancet 339, 1429–1432 (1992).
  Article CAS PubMed Google Scholar
• Ockenhouse, C. F. et al. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J. Infect. Dis. 177, 1664–16673 (1998).
  Article CAS PubMed Google Scholar
• Doehn, C., Kausch, I., Bohmer, T., Sommerauer, M. & Jocham, D. Drug evaluation: Therion's rV-PSA-TRICOM + rF-PSA-TRICOM prime–boost prostate cancer vaccine. Curr. Opin. Mol. Ther. 9, 183–189 (2007).
  CAS PubMed Google Scholar
• Rochlitz, C. et al. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J. Gene. Med. 5, 690–699 (2003).
  Article CAS PubMed Google Scholar
• Jager, E. et al. Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc. Natl Acad. Sci. USA 103, 14453–14458 (2006).
  Article PubMed PubMed Central CAS Google Scholar
• Wein, L. M., Wu, J. T. & Kirn, D. H. Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery. Cancer Res. 63, 1317–1324 (2003).
  CAS PubMed Google Scholar
• Mercer, J. & Helenius, A. Vaccinia virus uses macropinocytosis and apoptotic mimicry to enter host cells. Science 320, 531–535 (2008).
  Article CAS PubMed Google Scholar
• Moss, B. Poxvirus entry and membrane fusion. Virology 344, 48–54 (2006).
  Article CAS PubMed Google Scholar
• Vanderplasschen, A., Mathew, E., Hollinshead, M., Sim, R. B. & Smith, G. L. Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope. Proc. Natl Acad. Sci. USA 95, 7544–7549 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Bell, E. et al. Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin. Virology 325, 425–431 (2004).
  Article CAS PubMed Google Scholar
• Kirn, D. H., Wang, Y., Liang, W., Contag, C. H. & Thorne, S. H. Enhancing poxvirus oncolytic effects through increased spread and immune evasion. Cancer Res. 68, 2071–2075 (2008).
  Article CAS PubMed Google Scholar
• Wittek, R. Vaccinia immune globulin: current policies, preparedness, and product safety and efficacy. Int. J. Infect. Dis. 10, 193–201 (2006).
  Article PubMed Google Scholar
• De Clercq, E. Cidofovir in the treatment of poxvirus infections. Antiviral Res. 55, 1–13 (2002).
  Article CAS PubMed Google Scholar
• Yang, G. et al. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J. Virol. 79, 13139–13149 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Reeves, P. M. et al. Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nature Med. 11, 731–739 (2005).
  Article CAS PubMed Google Scholar
• Smith, G. L. & Moss, B. Infectious poxvirus vectors have capacity for at least 25000 base pairs of foreign DNA. Gene 25, 21–28 (1983).
  Article CAS PubMed Google Scholar
• Wang, F. et al. Disruption of Erk-dependent type I interferon induction breaks the myxoma virus species barrier. Nature Immunol. 5, 1266–1274 (2004).
  Article CAS Google Scholar
• Wang, G. et al. Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proc. Natl Acad. Sci. USA 103, 4640–4645 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Yu, Y. A. et al. Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. Nature Biotechnol. 22, 313–320 (2004).
  Article CAS Google Scholar
• Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000).
  Article CAS PubMed Google Scholar
• Katsafanas, G. C. & Moss, B. Vaccinia virus intermediate stage transcription is complemented by Ras-GTPase-activating protein SH3 domain-binding protein (G3BP) and cytoplasmic activation/proliferation-associated protein (p137) individually or as a heterodimer. J. Biol. Chem. 279, 52210–52217 (2004).
  Article CAS PubMed Google Scholar
• Yang, H. et al. Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. J. Clin. Invest. 115, 379–387 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Foloppe, J. et al. Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus. Gene Ther. 15, 1361–1371 (2008).
  Article CAS PubMed Google Scholar
• Zhang, Q. et al. Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Cancer Res. 67, 10038–10046 (2007).
  Article CAS PubMed Google Scholar
• Gnant, M. F. et al. Tumor-specific gene delivery using recombinant vaccinia virus in a rabbit model of liver metastases. J. Natl Cancer Inst. 91, 1744–1750 (1999).
  Article CAS PubMed Google Scholar
• Buller, R. M., Smith, G. L., Cremer, K., Notkins, A. L. & Moss, B. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature 317, 813–815 (1985).
  Article CAS PubMed Google Scholar
• Hengstschlager, M. et al. Different regulation of thymidine kinase during the cell cycle of normal versus DNA tumor virus-transformed cells. J. Biol. Chem. 269, 13836–13842 (1994).
  Article CAS PubMed Google Scholar
• Buller, R. M., Chakrabarti, S., Moss, B. & Fredrickson, T. Cell proliferative response to vaccinia virus is mediated by VGF. Virology 164, 182–192 (1988).
  Article CAS PubMed Google Scholar
• Tzahar, E. et al. Pathogenic poxviruses reveal viral strategies to exploit the ErbB signaling network. EMBO J. 17, 5948–5963 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• de Magalhaes, J. C. et al. A mitogenic signal triggered at an early stage of vaccinia virus infection: implication of MEK/ERK and protein kinase A in virus multiplication. J. Biol. Chem. 276, 38353–38360 (2001).
  Article CAS PubMed Google Scholar
• Alcami, A. & Smith, G. L. A soluble receptor for interleukin-1β encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection. Cell 71, 153–167 (1992).
  Article CAS PubMed Google Scholar
• Kettle, S. et al. Vaccinia virus serpin B13R (SPI-2) inhibits interleukin-1beta-converting enzyme and protects virus-infected cells from TNF- and Fas-mediated apoptosis, but does not prevent IL-1beta-induced fever. J. Gen. Virol. 78 (Pt 3), 677–685 (1997).
  Article CAS PubMed Google Scholar
• Taylor, J. M., Quilty, D., Banadyga, L. & Barry, M. The vaccinia virus protein F1L interacts with Bim and inhibits activation of the pro-apoptotic protein Bax. J. Biol. Chem. 281, 39728–39739 (2006).
  Article CAS PubMed Google Scholar
• Yang, S. et al. A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus. Gene Ther. 14, 638–647 (2007).
  Article PubMed CAS Google Scholar
• Colamonici, O. R., Domanski, P., Sweitzer, S. M., Larner, A. & Buller, R. M. Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon α transmembrane signaling. J. Biol. Chem. 270, 15974–15978 (1995).
  Article CAS PubMed Google Scholar
• Symons, J. A., Alcami, A. & Smith, G. L. Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell 81, 551–560 (1995).
  Article CAS PubMed Google Scholar
• Clarke, M. F. & Becker, M. W. Stem cells: the real culprits in cancer? Sci. Am. 295, 52–59 (2006).
  Article PubMed Google Scholar
• Clarke, M. F. & Fuller, M. Stem cells and cancer: two faces of eve. Cell 124, 1111–1115 (2006).
  Article CAS PubMed Google Scholar
• Lotze, M. T. & Tracey, K. J. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nature Rev. Immunol. 5, 331–342 (2005).
  Article CAS Google Scholar
• Rubartelli, A. & Lotze, M. T. Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox. Trends Immunol. 28, 429–436 (2007).
  Article CAS PubMed Google Scholar
• Zhu, J., Martinez, J., Huang, X. & Yang, Y. Innate immunity against vaccinia virus is mediated by TLR2 and requires TLR-independent production of IFN-β. Blood 109, 619–625 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Breitbach, C. J. et al. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol. Ther. 15, 1686–1693 (2007).
  Article CAS PubMed Google Scholar
• Gnant, M. F., Puhlmann, M., Alexander, H. R. Jr & Bartlett, D. L. Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor-specific gene expression and prolongation of survival in mice. Cancer Res. 59, 3396–3403 (1999).
  CAS PubMed Google Scholar
• Kumar, S., Gao, L., Yeagy, B. & Reid, T. Virus combinations and chemotherapy for the treatment of human cancers. Curr. Opin. Mol. Ther. 10, 371–379 (2008).
  PubMed Google Scholar
• Panchanathan, V., Chaudhri, G. & Karupiah, G. Protective immunity against secondary poxvirus infection is dependent on antibody but not on CD4 or CD8 T-cell function. J. Virol. 80, 6333–6338 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Naito, T., Kaneko, Y. & Kozbor, D. Oral vaccination with modified vaccinia virus Ankara attached covalently to TMPEG-modified cationic liposomes overcomes pre-existing poxvirus immunity from recombinant vaccinia immunization. J. Gen. Virol. 88, 61–70 (2007).
  Article CAS PubMed Google Scholar
• Green, N. K. et al. Retargeting polymer-coated adenovirus to the FGF receptor allows productive infection and mediates efficacy in a peritoneal model of human ovarian cancer. J. Gene. Med. 10, 280–289 (2008).
  Article CAS PubMed Google Scholar
• Blasco, R., Sisler, J. R. & Moss, B. Dissociation of progeny vaccinia virus from the cell membrane is regulated by a viral envelope glycoprotein: effect of a point mutation in the lectin homology domain of the A34R gene. J. Virol. 67, 3319–3325 (1993).
  Article CAS PubMed PubMed Central Google Scholar
• Katz, E., Ward, B. M., Weisberg, A. S. & Moss, B. Mutations in the vaccinia virus A33R and B5R envelope proteins that enhance release of extracellular virions and eliminate formation of actin-containing microvilli without preventing tyrosine phosphorylation of the A36R protein. J. Virol. 77, 12266–12275 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Thorne, S. H., Negrin, R. S. & Contag, C. H. Synergistic antitumor effects of immune cell–viral biotherapy. Science 311, 1780–1784 (2006).
  Article CAS PubMed Google Scholar
• Cole, C. et al. Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells. Nature Med. 11, 1073–1081 (2005).
  Article CAS PubMed Google Scholar
• Qiao, J. et al. Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy. Nature Med. 14, 37–44 (2008).
  Article CAS PubMed Google Scholar
• Power, A. T. et al. Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity. Mol. Ther. 15, 123–130 (2007).
  Article CAS PubMed Google Scholar
• Ong, H. T., Hasegawa, K., Dietz, A. B., Russell, S. J. & Peng, K. W. Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies. Gene Ther. 14, 324–333 (2006).
  Article PubMed CAS Google Scholar
• Chang, H. Y. et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc. Natl Acad. Sci. USA 102, 3738–3743 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Morgan, R. A. et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126–129 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Herberman, R. B. Cancer immunotherapy with natural killer cells. Semin. Oncol. 29, 27–30 (2002).
  Article CAS PubMed Google Scholar
• Baker, J., Verneris, M. R., Ito, M., Shizuru, J. A. & Negrin, R. S. Expansion of cytolytic CD8+ natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon γ production. Blood 97, 2923–2931 (2001).
  Article CAS PubMed Google Scholar
• Chakrabarti, S., Sisler, J. R. & Moss, B. Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques 23, 1094–1097 (1997).
  Article CAS PubMed Google Scholar
• Davison, A. J. & Moss, B. Structure of vaccinia virus late promoters. J. Mol. Biol. 210, 771–784 (1989).
  Article CAS PubMed Google Scholar
• Banaszynski, L. A., Sellmyer, M. A., Contag, C. H., Wandless, T. J. & Thorne, S. H. Chemical control of protein stability and function in living animals. Nature Med. 14, 1123–1127 (2008).
  Article CAS PubMed Google Scholar
• Hodge, J. W. et al. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res. 59, 5800–5807 (1999).
  CAS PubMed Google Scholar
• Thorne, S. H., Tam, B. Y., Kirn, D. H., Contag, C. H. & Kuo, C. J. Selective intratumoral amplification of an antiangiogenic vector by an oncolytic virus produces enhanced antivascular and anti-tumor efficacy. Mol. Ther. 13, 938–946 (2006).
  Article CAS PubMed Google Scholar
• Kim, J. H. et al. Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy. J. Natl Cancer Inst. 98, 1482–1493 (2006).
  Article CAS PubMed Google Scholar
• McCart, J. A. et al. Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression. Gene Ther. 7, 1217–1223 (2000).
  Article CAS PubMed Google Scholar
• Chalikonda, S. et al. Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene. Cancer Gene Ther. 15, 115–125 (2008).
  Article CAS PubMed Google Scholar
• Smith, G. L., Symons, J. A., Khanna, A., Vanderplasschen, A. & Alcami, A. Vaccinia virus immune evasion. Immunol. Rev. 159, 137–154 (1997).
  Article CAS PubMed Google Scholar
• Thorne, S. H. & Contag, C. H. Using in vivo bioluminescence imaging to shed light on cancer biology. Proc. IEEE 93, 750–762 (2005).
  Article CAS Google Scholar
• Luker, K. E., Hutchens, M., Schultz, T., Pekosz, A. & Luker, G. D. Bioluminescence imaging of vaccinia virus: effects of interferon on viral replication and spread. Virology 341, 284–300 (2005).
  Article CAS PubMed Google Scholar
• Gross, S. & Piwnica-Worms, D. Spying on cancer: molecular imaging in vivo with genetically encoded reporters. Cancer Cell 7, 5–15 (2005).
  CAS PubMed Google Scholar
• Groot-Wassink, T., Aboagye, E. O., Glaser, M., Lemoine, N. R. & Vassaux, G. Adenovirus biodistribution and noninvasive imaging of gene expression in vivo by positron emission tomography using human sodium/iodide symporter as reporter gene. Hum. Gene Ther. 13, 1723–1735 (2002).
  Article CAS PubMed Google Scholar
• McCart, J. A. et al. Oncolytic vaccinia virus expressing the human somatostatin receptor SSTR2: molecular imaging after systemic delivery using 111In-pentetreotide. Mol. Ther. 10, 553–561 (2004).
  Article CAS PubMed Google Scholar
• Weissleder, R. et al. In vivo magnetic resonance imaging of transgene expression. Nature Med. 6, 351–355 (2000).
  Article CAS PubMed Google Scholar
• Halsell, J. S. et al. Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel. JAMA 289, 3283–3289 (2003).
  Article PubMed Google Scholar
• Kwak, H., Horig, H. & Kaufman, H. L. Poxviruses as vectors for cancer immunotherapy. Curr. Opin. Drug Discov. Devel. 6, 161–168 (2003).
  CAS PubMed Google Scholar
• Essajee, S. & Kaufman, H. L. Poxvirus vaccines for cancer and HIV therapy. Expert Opin. Biol. Ther. 4, 575–588 (2004).
  Article CAS PubMed Google Scholar
• Arlen, P. M., Kaufman, H. L. & DiPaola, R. S. Pox viral vaccine approaches. Semin. Oncol. 32, 549–555 (2005).
  Article CAS PubMed Google Scholar
• Hunter-Craig, I., Newton, K. A., Westbury, G. & Lacey, B. W. Use of vaccinia virus in the treatment of metastatic malignant melanoma. BMJ 2, 512–515 (1970).
  Article CAS PubMed PubMed Central Google Scholar
• Roenigk, H. H. Jr, Deodhar, S., St Jacques, R. & Burdick, K. Immunotherapy of malignant melanoma with vaccinia virus. Arch. Dermatol. 109, 668–673 (1974).
  Article PubMed Google Scholar
• Burdick, K. H. Malignant melanoma treated with vaccinia injections. Arch. Dermatol. 82, 438–439 (1960).
  Google Scholar
• Mastrangelo, M. J., Maguire, H. C. & Lattime, E. C. Intralesional vaccinia/GM-CSF recombinant virus in the treatment of metastatic melanoma. Adv. Exp. Med. Biol. 465, 391–400 (2000).
  Article CAS PubMed Google Scholar
• Belisario, J. C. & Milton, G. W. The experimental local therapy of cutaneous metastases of malignant melanoblastomas with cow pox vaccine or colcemid (demecolcine or omaine). Aust. J. Dermatol. 6, 113–118 (1961).
  Article CAS PubMed Google Scholar
• Lee, S. S., Eisenlohr, L. C., McCue, P. A., Mastrangelo, M. J. & Lattime, E. C. Intravesical gene therapy: in vivo gene transfer using recombinant vaccinia virus vectors. Cancer Res. 54, 3325–3328 (1994).
  CAS PubMed Google Scholar
• Mastrangelo, M. J. et al. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther. 6, 409–422 (1999).
  Article CAS PubMed Google Scholar
• Choi, H. et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J. Clin. Oncol. 25, 1753–1759 (2007).
  Article PubMed Google Scholar
• Ramesh, N. et al. CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor–armed oncolytic adenovirus for the treatment of bladder cancer. Clin. Cancer Res. 12, 305–313 (2006).
  Article CAS PubMed Google Scholar
• Hu, J. C. et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin. Cancer Res. 12, 6737–6747 (2006).
  Article CAS PubMed Google Scholar